Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

Inclusion Criteria: Subjects must: * Be capable of understanding the purpose and risks of the study and sign a written Informed Consent Form (ICF); Legally authorized representative of subjects willing and able to give consent for children 5-18 yo * Be male or female with a diagnosis of EBS * Minimum EBDASI feet activity score of 2/10 * Age - 5 years or older * Ability to complete 12 study visits within a 40-week period, each for approximately 30-60 minutes. Anticipated life expectancy ≥52 weeks * Males and females of childbearing potential should be using an effective means of contraception. * Laboratory values within the range of normal for the participating institution unless the PI feels they are not clinically relevant * Be able to comply with all study requirements Exclusion Criteria: * Allergy to sirolimus or components of the vehicle ointment * Pregnancy, breast feeding * Prior history of liver disease * Serious known concurrent medical illness or infection, which could potentially present a safety risk and/or prevent compliance with the requirements of the treatment program. * Known immunodeficiency virus or syndrome including those with: * Acquired Immunodeficiency Syndrome (AIDS) * Human Immunodeficiency Virus (HIV) * Hepatitis B * Prior history of grafting surgeries or other surgeries in the dermatologic treatment area * History of significant condition in the dermatologic treatment area such as trauma, which could impair evaluation for the treatment of EBS …